Restem Group Inc.
June 23, 2026
Theater 3
Type: Company Presentation
Focus Area:
Cell and Gene Therapy and Genome Editing
RESTEM is a leading clinical-stage biotechnology company focused on developing off-the-shelf, next-generation cell therapies for autoimmune, inflammatory, and age-related diseases. Leveraging proprietary products, deep clinical expertise, and advanced manufacturing capabilities, RESTEM is advancing two potentially transformative programs, Restem-L, our umbilical cord lining progenitor cells (UMPCs) therapy for autoimmune diseases, and activated natural killer cell (aNK) therapeutics targeting senescence and age-associated disorders. Our therapies are designed to reprogram the immune system rather than focusing solely on symptom management, offering patients with limited options the potential to address underlying disease mechanisms. RESTEM is headquartered in Miami, Florida.
Company HQ City:
Miami
Company HQ State:
FL
Company HQ Country:
United States
Year Founded:
2018
Lead Product in Development:
Restem-L
CEO
Andres Isaias
Development Phase of Lead Product
Phase II
When you expect your next catalyst update?
December 2026
Speakers
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}